The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Serotonin Reuptake Inhibitor Withdrawal
Abstract
We studied reported withdrawal symptoms in a retrospective chart review of 352 patients treated in an outpatient clinic with the nonselective serotonin reuptake inhibitor clomipramine or with one of the selective serotonin reuptake inhibitors (SSRIs), fluoxetine, fluvoxamine, paroxetine, or sertraline. In 171 patients who were supervised during medication tapering and discontinuation, the most common symptoms were dizziness, lethargy, paresthesia, nausea, vivid dreams, irritability, and lowered mood. When patients with at least one qualitatively new symptom were defined as cases, these symptoms occurred significantly more frequently in patients who had been treated either with one of the shorter half-life SSRIs, fluvoxamine or paroxetine (17.2%), or with clomipramine (30.8%), than in patients taking one of the SSRIs with longer half-life metabolites, sertraline or fluoxetine (1.5%). The rate was not significantly different between the different shorter half-life treatments. Cases treated with fluvoxamine or paroxetine had received a significantly longer period of treatment (median 28 weeks) than noncases (16 weeks), but there were no significant associations with age or with diagnostic grouping. There was a trend toward an association with male sex. The majority of cases occurred despite slowly tapered withdrawal. Symptoms persisted for up to 21 days (mean = 11.8 days) after onset. These symptoms were relieved within 24 hours by restarting the medication, but were not relieved by benzodiazepines or by moclobemide. A role has been suggested for serotonin in coordinating sensory and autonomic function with motor activity. We suggest that this may lead to useful hypotheses about the pathophysiology of withdrawal symptoms from serotonin reuptake inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Current advances and trends in the treatment of depression
Blier, P., & de Montigny, C. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90315-8 · Cited by 1,113
5-HT and motor control: a hypothesis
Jacobs, B. L., & Fornal, C. A. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90090-9 · Cited by 451
Binding of antidepressants to human brain receptors: focus on newer generation compounds
Cusack, B., Nelson, A., & Richelson, E. (1994) · Psychopharmacology · doi:10.1007/bf02244985 · Cited by 349
Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro.
Richelson, E., & Nelson, A. (1984) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21446-x · Cited by 341
Clinical Pharmacokinetics of Selective Serotonin Reuptake Inhibitors
van Harten, J. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324030-00003 · Cited by 311
Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study
Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., & Manniche, P. M. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.3.374 · Cited by 261
Bel, N., & Artigas, F. (1993) · Synapse · doi:10.1002/syn.890150310 · Cited by 237
Waterhouse, B. D., Ausim Azizi, S., Burne, R. A., & Woodward, D. J. (1990) · Brain Research · doi:10.1016/0006-8993(90)91422-d · Cited by 194
The abrupt discontinuation of fluvoxamine in patients with panic disorder.
Black, D. W., Wesner, R. B., & Gabel, J. (1993) · PubMed · Cited by 77
Antiemetic Effects of Serotonergic 5-HT1A-Receptor Agonists in Suncus Murinus
Okada, F., Torii, Y., Saitō, H., & Matsuki, N. (1994) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.64.109 · Cited by 77
Research works printed but not linked: 9
- Stoukides, 1991, Am J Psychiatry, 148, 1263
- Black, 1993, J Clin Psychiatry, 54, 146
- 1993, harmacovigilance, 19, 1
- Louie, 1994, Am J Psychiatry, 151, 450
- Debattista, 1995, Am J Psychiatry, 152, 1235
- Einbinder, 1995, Am J Psychiatry, 152, 1235
- Frost, 1995, Am J Psychiatry, 152, 810
- Pyke, 1995, Am J Psychiatry, 152, 149
- Richelson, 1984, J Pharmacol Exp Ther, 230, 94
Cited by
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,510
Effects of SSRIs on Sexual Function: A Critical Review
Rosen, R. C., Lane, R. M., & Menza, M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00013 · Cited by 650
Malhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614
“, 2006) but is more anticholinergic than other SSRIs and patients are more prone to develop discontinuation effects if it is stopped suddenly (Coupland et al., 1996).”
BackgroundFava, M., & Kendler, K. S. (2000) · Neuron · doi:10.1016/s0896-6273(00)00112-4 · Cited by 603
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
“…nausea, vomiting, diarrhea, movement disorders, insomnia, irritability, visual disturbance, lethargy, anorexia, tremor, electric shock sensations, and lowered mood have all been reported in association with cessation of SSRI treatment (Coupland et al 1996; Lejoyeux et al 1996; Price et al 1996).”
BackgroundMethod
Metadata
- Authors
- Coupland, N. J., Bell, C. J., & Potokar, J. P.
- Affiliations
- University of Alberta (CA)
- ORCID
- Bell, Caroline J.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1996-10
- Volume
- 16
- Issue
- 5
- Pages
- 356-362
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2038826787
- Cited by
- 303
- References
- 25
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 6 · 2023: 2 · 2022: 5 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 7 · 2017: 5 · 2016: 7 · 2015: 5 · 2014: 4 · 2013: 9 · 2012: 10
- FWCI
- 21.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- selective serotonin reuptake inhibitors, clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, drug discontinuation, medication tapering, elimination half-life, withdrawal symptoms, benzodiazepines, moclobemide, serotonin
- MeSH terms
- Adolescent, Adult, Age Factors, Clomipramine, Dizziness, Female, Humans, Male, Middle Aged, Paresthesia, Retrospective Studies, Sex Factors, Substance Withdrawal Syndrome, 1-Naphthylamine, Fluvoxamine, Selective Serotonin Reuptake Inhibitors, Paroxetine, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serotonin Reuptake Inhibitor Withdrawal. https://app.cochat.ai/papers/10.1097/00004714-199610000-00003
- The paper
- Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996). Serotonin Reuptake Inhibitor Withdrawal. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199610000-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.